**Supplementary Fig. 9. Forest plot of SAEs associated with SOF-based DAA drug treatment of decompensated and compensated hepatitis C cirrhosis patients.** The incidence of SAEs was significantly higher in patients with decompensated hepatitis C cirrhosis than that in compensated patients: 16.2% (95% CI: 10.8–22.4) vs. 2.8% (95% CI: 0.9–5.7) *p<*0.0001). SOF, sofosbuvir; SAE, serious adverse events; DC, decompensated cirrhosis; CC, compensated cirrhosis.

